(AI video summary)
This video was created on 23 September 2025 for IG audiences by ausbiz.
ASX code: TLX
Reimbursement approval sparks optimism
Telix Pharmaceuticals announced that the United States (US) Centers for Medicare and Medicaid Services approved reimbursement for their prostate cancer imaging agent. Last Friday, Citi began coverage on Telix with a high-risk ‘buy’ rating, forecasting that the company’s base business will exceed market expectations
Market reaction
Telix shares rose 5.6%, showing increased investor confidence. Analysts noted that the company’s shares were set for a positive turn following previous regulatory setbacks on two drugs, where the Food and Drug Administration (FDA) requested more information, rather than rejections. Analysts have upgraded their outlook from ‘hold’ to ‘buy’, anticipating further positive announcements.
Investment outlook
The recent government funding approval boosts the company’s financial outlook. Analysts suggest that if positive updates continue, Telix’s stock may rise 60 to 80% in line with analysts’ price targets. However, they suggest focusing on the business’s prospects over the volatile share price.
www.ig.com